Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from patient's legal guardian or legal representative~* 18 - 65 years of age, inclusive~* Head trauma within the last 12 hours~* Traumatic brain injury with Glasgow Coma Score (GCS) ≥ 5 and that requires ICP monitoring~* Catheter placement for monitoring and management of increased ICP~* Microdialysis probe placement in penumbra zone or ipsilateral to contusion if focal~* Systolic blood pressure ≥ 100 mmHg~* Females of child-bearing potential must have a negative pregnancy test~Exclusion Criteria:~* Penetrating head injury (e.g. missile, stab wound)~* Not expected to survive more than 24 hours after admission~* Concurrent, but not pre-existing, spinal cord injury~* Unilateral and bilateral fixed and dilated pupil (\> 4 mm)~* Cardiopulmonary resuscitation performed post injury~* continuing bleeding likely to require multiple transfusions (\> 4 units red blood cells)~* Coma due to a pure epidural hematoma (lucid interval and absence of structural brain damage on CT scan)~* Coma suspected to be primarily due to other causes than head injury (e.g. drug overdose)~* Known or CT scan evidence of pre-existing major cerebral damage~* Decompressive craniectomy, planned prior to randomization~* Polytraumatic patients with Injury Severity Score \> 25, or rhabdomyolysis~* Injuries to ascending aorta and/or carotid arteries~* serum creatinine values \> 1.5 mg/dL~* estimated Glomerular Filtration Rate \< 60 ml/min (MDRD-formula)~* body mass index (BMI) \> 35, Body weight \> 120 kg~* Any severe concomitant condition (cancer; hematologic, renal, hepatic, coronary disease; major psychiatric disorder; alcohol or drug abuse), that can be ascertained at admission~* Known to have received an experimental drug within 4 weeks prior to current injury~* Administration of \> 100 ml of contrast media containing iodine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VAS203 15 mg/kg (Type: EXPERIMENTAL): Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
- VAS203 20 mg/kg (Type: EXPERIMENTAL): 10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
- VAS203 30 mg/kg (Type: EXPERIMENTAL): 10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
- Saline (Type: PLACEBO_COMPARATOR): 0.9 % Sodium chloride infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).